HealthProves
Home/Manufacturers/Advanced Rx Pharmacy of Tennessee, LLC
Manufacturer profile

Advanced Rx Pharmacy of Tennessee, LLC

Pharmaceutical company7 products tracked
7
products tracked
534,096
total reports
399
recalls on record
78.9%
serious overall
Products
showing 7 of 7
ProductApprovedReports ↓Top signalRecalls
1958303,290Plasma cell myeloma81
1957167,055Infusion related reaction93
196417,730Myelosuppression64
198316,671Chondrolysis100
198314,926Chondrolysis10
19597,797Food allergy43
—6,627Pulmonary mass8
Recall history · 50 on record
DateClassReasonFirm
Apr 2, 2026IILack of Assurance of SterilityHuons Co., Ltd.
Feb 4, 2026IIFailed Impurities/Degradation Specifications - OOS impurities result observed during long term stability testing at product expiry (24 months) were above specs for these impurities: Dexamethasone Sodium Phosphate EP impurity G (Impurity RU 49336) and dexamethasone formate.SOMERSET THERAPEUTICS LLC
Jan 15, 2026IILabeling: Not Elsewhere Classified. Incorrect orientation of the blister foil applied to the blister cavities, which results in incorrect dosing information when following the directions on the foil.Greenstone Llc
Dec 18, 2025IIPresence of particulate matter - Glass like particles.Imprimis NJOF, LLC
Dec 18, 2025IIPresence of particulate matter - Glass like particles.Imprimis NJOF, LLC
Apr 15, 2025IILabeling: Incorrect or Missing Lot and/or Expiration date: Individual vials of Dexonto 0.4%, are labeled correctly with the BUD of 12/25/2024, however, the outer box on some of the Dexonto 0.4% are labeled incorrectly with a BUD of 12/25/2025.Nubratori, Inc
Mar 6, 2025IILack of Assurance of SterilityQuVa Pharma, Inc.
May 23, 2024IIFailed Impurities/Degradation Specifications: impurity sulfonic acid adduct of dexamethasone phosphate results were above spec.Eugia US LLC
May 14, 2024IILack of Assurance of SterilityImprimis NJOF, LLC
May 14, 2024IILack of Assurance of SterilityImprimis NJOF, LLC
Apr 25, 2024IIPresence of Particulate Matter: Potential for black particulates in the drug product.Sagent Pharmaceuticals
Feb 20, 2024IIFailed Dissolution SpecificationsEugia US LLC
Nov 9, 2023IILack of Assurance of SterilitySCA Pharmaceuticals, LLC
Sep 21, 2023IILack of assurance of sterility:Central Admixture Pharmacy Services Inc
Jul 17, 2023IILack of assurance of sterility: Lack of validation data for sanitization cyclesCentral Admixture Pharmacy Services Inc
May 8, 2023IIILabeling: Not Elsewhere Classified; A typographical error was observed in the NDC number on the preprinted Individual Folding Cartons (secondary packaging only). Incorrect NDC Number 70121-1573-1; Correct NDC Number 70121-1574-1.Amneal Pharmaceuticals of New York, LLC
Dec 27, 2022IILack of sterility assuranceSentara Infusion Services
Dec 22, 2022IILack of Assurance of Sterility: FDA inspection revealed insanitary conditions at the facility.Pharmacy Innovations
Nov 22, 2022IISubpotent Drug: Testing results below the defined limit for the epinephrine portion of this product.Fresenius Kabi USA, LLC
Jul 27, 2022IILack of Assurance of SterilityPine Pharmaceuticals, LLC
Jun 30, 2022IILack of Assurance of SterilityNephron Sterile Compounding Center LLC
Apr 13, 2022IIcGMP deviations: Temperature abuseMckesson Medical-Surgical Inc. Corporate Office
Apr 13, 2022IIcGMP deviations: Temperature abuseMckesson Medical-Surgical Inc. Corporate Office
Apr 13, 2022IIcGMP deviations: Temperature abuseMckesson Medical-Surgical Inc. Corporate Office
Apr 13, 2022IIcGMP deviations: Temperature abuseMckesson Medical-Surgical Inc. Corporate Office
Apr 13, 2022IIcGMP deviations: Temperature abuseMckesson Medical-Surgical Inc. Corporate Office
Apr 13, 2022IIcGMP deviations: Temperature abuseMckesson Medical-Surgical Inc. Corporate Office
Apr 13, 2022IIcGMP deviations: Temperature abuseMckesson Medical-Surgical Inc. Corporate Office
Apr 13, 2022IIcGMP deviations: Temperature abuseMckesson Medical-Surgical Inc. Corporate Office
Apr 13, 2022IIcGMP deviations: Temperature abuseMckesson Medical-Surgical Inc. Corporate Office
Apr 13, 2022IIcGMP deviations: Temperature abuseMckesson Medical-Surgical Inc. Corporate Office
Apr 13, 2022IIcGMP deviations: Temperature abuseMckesson Medical-Surgical Inc. Corporate Office
Apr 13, 2022IIcGMP deviations: Temperature abuseMckesson Medical-Surgical Inc. Corporate Office
Apr 13, 2022IIcGMP deviations: Temperature abuseMckesson Medical-Surgical Inc. Corporate Office
Apr 13, 2022IIcGMP deviations: Temperature abuseMckesson Medical-Surgical Inc. Corporate Office
Apr 13, 2022IIcGMP deviations: Temperature abuseMckesson Medical-Surgical Inc. Corporate Office
Apr 13, 2022IIcGMP deviations: Temperature abuseMckesson Medical-Surgical Inc. Corporate Office
Apr 1, 2022IIISubpotentJubilant Cadista Pharmaceuticals, Inc.
Feb 21, 2022IIFailed Impurities/Degradation Specifications: higher than permissible levels of unknown impurities were found in the drug product.Morton Grove Pharmaceuticals, Inc.
Dec 31, 2021IILack of Assurance of SterilityTeva Pharmaceuticals USA
Dec 6, 2021IICGMP DeviationsEdge Pharma, LLC
Dec 6, 2021IILack of Assurance of SterilityEdge Pharma, LLC
Jul 29, 2021IILack of Assurance of SterilityTeva Pharmaceuticals USA
Jul 29, 2021IILack of Assurance of SterilityTeva Pharmaceuticals USA
May 3, 2021ILabeling: Label Mix-Up: some vials labeled to contain 0.5% Bupivacaine Hydrochloride Injection, USP may contain 1% Lidocaine HCl Injection, USP and some vials labeled to contain 1% Lidocaine HCl Injection, USP may contain 0.5% Bupivacaine Hydrochloride Injection, USPPFIZER, INC
Apr 26, 2021IILack of Assurance of SterilityTeva Pharmaceuticals USA
Mar 19, 2021IIILabeling: Illegible label: Manufacturer received complaint of mis-alignment print of the printed dosing instructions on the blister card.Asclemed USA Inc. dba Enovachem Pharmaceuticals
Feb 19, 2021IIILabeling: Illegible label: Customer complaint received of mis-alignment print of the printed dosing instructions on the blister card.Jubilant Cadista Pharmaceuticals, Inc.
Dec 17, 2020IILack of assurance of sterility: 13 vials were discovered to have faulty crimps.Imprimis NJOF, LLC
Dec 10, 2020IISubpotent Drug: Low out-of-specification assay results for the epinephrine component.Fresenius Kabi USA, LLC

Class I = reasonable probability of serious harm · Class II = temporary or reversible · Class III = unlikely to cause harm.

Registration status

Some products from Advanced Rx Pharmacy of Tennessee, LLC are not FDA-registered for human use. For unregistered substances (peptides, SARMs without human registration), no legitimate human-use supplier exists. The absence of a sourcing route is the safety information.